Evotec acquires Aptuit
With its acquisition of Aptuit, the biotechnology company Evotec intends to strengthen its position as a leading provider of drug research and development services. Aptuit,…
clement02.08.2017
Interest from startups in the BaseLaunch healthcare accelerator exceeds expectations
More than 100 projects from Switzerland and abroad competed for a place in the BaselArea.swiss accelerator program for healthcare startups By the closing date of…
clement25.07.2017
“I want to turn innovative research into new drugs”
Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the…
clement04.07.2017
“I want to turn innovative research into new drugs”, Interview with Dr. Michael Bauer, CEO of Cellestia
Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the…
clement20.06.2017
Basilea concludes license agreement with Pfizer
The Basel-based pharmaceutical company Basilea has entered into a license agreement with the US company Pfizer for its antifungal Cresemba.
clement15.06.2017
